Loading clinical trials...
Loading clinical trials...
Phase 2, Open-Label, Single Arm, Multi-Center Study to Assess the Efficacy and Safety of BST-236 as a Single Agent in Adults Unfit for Intensive Chemotherapy With Relapsed or Refractory Acute Myeloid Leukemia or HR-MDS .
Conditions
Interventions
BST-236
Locations
17
France
CHU NIMES Caremeau
Nîmes, Nîmes, France
Centre Henri Becquerel
Rouen, Rouen, France
CHU Amiens
Amiens, France
CHU d'Angers
Angers, France
CHU Besançon - Hôpital Jean Minjoz
Besançon, France
CHU de Bordeaux Haut-Lévèque
Bordeaux, France
Start Date
May 1, 2021
Primary Completion Date
January 13, 2025
Completion Date
January 13, 2025
Last Updated
May 18, 2025
NCT06285890
NCT06220162
NCT04065399
NCT06994676
NCT04628026
NCT06484062
Lead Sponsor
Groupe Francophone des Myelodysplasies
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions